Application of a TNF-alpha-inhibitor into the scala tympany after cochlear electrode insertion trauma in guinea pigs: Preliminary audiologic results

Ihler, Friedrich; Pelz, Sabrina; Coors, Melanie; Matthias, Christoph; Canis, Martin

doi:10.3109/14992027.2014.938369

Cited by 17 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FTY-720 indicates Fingolimod; TNF, tumor necrosis factor. drop in partial oxygen pressure (1) and thus eventually ischemia and subsequent apoptosis of inner hair cells, FTY-720 might be a promising agent fit for clinical testing in various inner ear pathologies, including sudden sensorineural hearing loss (4,6), noise trauma (3), as well as physical trauma to the cochlea (11). As an additional benefit in comparison to other drugs that have been suggested as treatments for these pathologies, such as AM-111 (30) or JTE-013 (6), FTY-720 has already been approved for clinical use in relapsing remitting multiple sclerosis and, thus, has a well known safety profile.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow

Bertlich¹,

Ihler²,

Weiss³

et al. 2017

Otology &Amp; Neurotology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…It has also been established that TNF is capable of impairing local circulation in various tissues, including the cochlea (6,10). Moreover, several studies have been able to demonstrate that TNF is involved in a number of inner ear pathologies, such as sudden sensorineural hearing loss (6), acoustic (3), and physical trauma (11).…”

mentioning

confidence: 99%

Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow

Bertlich¹,

Ihler²,

Weiss³

et al. 2017

Otology &Amp; Neurotology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Currently, research is focused on the application of glucocorticosteroids and antiapoptotic substances. These applications are aimed at minimizing fibrosis and hearing loss due to surgical trauma caused by insertion of the CI electrode [ 11 , 19 , 63 ]. The objective is to preserve residual hearing for combined electro-acoustic stimulation (EAS or Hybrid CI).…”

Section: Drugs Delivered In Combination With Cochlear Implantationmentioning

confidence: 99%

Intracochlear drug delivery in combination with cochlear implants

Plontke

Götze

Rahne

et al. 2016

HNO

View full text Add to dashboard Cite

Local drug application to the inner ear offers a number of advantages over systemic delivery. Local drug therapy currently encompasses extracochlear administration (i. e., through intratympanic injection), intracochlear administration (particularly for gene and stem cell therapy), as well as various combinations with auditory neurosensory prostheses, either evaluated in preclinical or clinical studies, or off-label. To improve rehabilitation with cochlear implants (CI), one focus is the development of drug-releasing electrode carriers, e. g., for delivery of glucocorticosteroids, antiapoptotic substances, or neurotrophins to the inner ear. The performance of cochlear implants may thus be improved by protecting neuronal structures from insertion trauma, reducing fibrosis in the inner ear, and by stimulating growth of neuronal structures in the direction of the electrodes. Controlled drug release after extracochlear or intracochlear application in conjunction with a CI can also be achieved by use of a biocompatible, resorbable controlled-release drug-delivery system. Two case reports for intracochlear controlled release drug delivery in combination with cochlear implants are presented. In order to treat progressive reduction in speech discrimination and increased impedance, two cochlear implant patients successfully underwent intracochlear placement of a biocompatible, resorbable drug-delivery system for controlled release of dexamethasone. The drug levels reached in inner ear fluids after different types of local drug application strategies can be calculated using a computer model. The intracochlear drug concentrations calculated in this way were compared for different dexamethasone application strategies.

show abstract

“…Optimization of the electrode nerve interface could be achieved by introducing drug substances into the cochlea which could cause the growth of neurites to the electrode [21,22].…”

Section: Researches On Optimizing the Performance Of Current Implantsmentioning

confidence: 99%

“…[37] Substances that may be introduced may be -antioxidants (trolox, ascorbic acid). In animal experiments, the introduction of antioxidants into the cochlea causes increased electrical thresholds [22].…”

Section: Researches On Optimizing the Performance Of Current Implantsmentioning

confidence: 99%

Cochlear Implant Strategies and Biomaterials from Past to Future

Martu¹,

Cozma²,

Martu³

et al. 2017

Mat.Plast.

View full text Add to dashboard Cite

The cochlear implant (C.I.) is a neurobionic prosthesis, being one of the greatest achievements of auditory neuroscience. Although C.I. represents the gold standard in the treatment of deafness in both the child and the adult, some problems like perception of speech in noise (atmosphere, environment), perception of music, binaural hearing remain, aspect to which improvements are expected. The article (this review) revises the road from the first attempts to cochlear implantation to today�s modern and reliable cochlear implant. Continuous improvement of existing technology both in terms of biomaterials used and in terms of speech processing and simultaneous stimulation strategies, promise with certainty the introduction of C.I. with superior performance. A look in the future is through new ideas and techniques, which await the transition from the experimental to the clinical stage in the emergence of a new generation of implants.

show abstract

Application of a TNF-alpha-inhibitor into the scala tympany after cochlear electrode insertion trauma in guinea pigs: Preliminary audiologic results

Abstract: The application of etanercept led to preservation of acoustic hearing after cochlear implantation trauma.

Cited by 17 publications

References 43 publications

Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow

Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow

Intracochlear drug delivery in combination with cochlear implants

Cochlear Implant Strategies and Biomaterials from Past to Future

Contact Info

Product

Resources

About